Latest News
Wisconsin Health News
The University of Wisconsin-Madison is launching a center to coordinate ongoing research and education in psychedelic compounds, including their use in treating substance abuse and psychiatric disorders.
The Transdisciplinary Center for Research in Psychoactive Substances, housed at the UW-Madison School of Pharmacy, will study the science, history and cultural impact of psychedelic agents, including their therapeutic potential.
“Psychoactive agents are the new frontier for potential new therapies and medications,” Paul Hutson, founding center director and a UW pharmacy professor, said in a statement.
Four clinical trials are currently underway on campus, including studying the effects of MDMA, or ecstasy, in treating post-traumatic stress disorder and psilocybin, also known as “magic mushrooms,” in treating depression and opioid addiction. Hutson anticipates federal approval for both substances within the next five years.
The center also seeks to increase participation in research by underrepresented groups.
And it will partner on the pharmacy school’s master’s of science program in psychoactive pharmaceutical investigation, the first accredited U.S. degree focused on the study and therapeutic development of psychedelic compounds and related drugs.
“We plan to continue being on the forefront of this field with innovation and development of novel therapies through our research and educational programs on psychoactive agents,” Hutson said.
The Usona Institute, a nonprofit medical research organization that supports work on consciousness-expanding medicine, also aims to be a center for psychedelic science and education. It broke ground earlier this month on a new campus in Fitchburg.
Wisconsin Department of Health Services
The Wisconsin Department of Health Services (DHS) is collaborating with three health care providers in different areas of the state to pilot a new approach to treating eligible BadgerCare Plus and Medicaid members who have substance use disorders and at least one other health condition. These providers will use an innovative “hub and spoke” program design to expand beyond traditional substance use disorder treatment services. Wisconsinites served by this new program will include people enrolled in BadgerCare Plus and Medicaid who are struggling with substance use disorders and also have other health conditions that create barriers to their recovery from addiction. The pilot sites will use a “hub and spoke” model to provide integrated services that give eligible members rapid access to comprehensive addiction and mental health treatment, primary care, and other needed supports to assist their recovery.
“It is past time to get folks the help they need in the way they need it, and we are excited to bring this proven strategy to Wisconsin,” said Governor Tony Evers. “By connecting the dots between substance use disorder treatment and other services, this new model will help us move the needle on ensuring access and effective care for our Wisconsin neighbors who are currently struggling.”
Read more.
Four Wisconsin organizations will receive $1 million each in federal funds to strengthen and expand substance use disorder prevention, treatment and recovery in rural areas.
The recently announced allocations come from the U.S. Department of Health and Human Services’ Health Resources and Services Administration.
Recipients include Duluth Clinic in Ashland, MetaStar in Madison, the Sokaogon Chippewa Community and Hospital Sisters Health System St. Joseph Hospital in Chippewa Falls.
Marinette County Group Home Association will also receive $500,000 under a separate grant program to help patients who misuse psychostimulants.
Biden-Harris Administration Provides $90 Million to Improve Health Care in Rural Communities
The Biden-Harris Administration announced today that it is providing nearly $90 million to help rural communities combat opioid use disorders (OUD) and other forms of substance use disorders (SUD), and to improve access to maternal and obstetrics care. This funding is being distributed by the U.S. Department of Health and Human Services (HHS) through the Health Resources and Services Administration (HRSA).
"These investments address a wide range of critical issues the Biden-Harris Administration is focused on to improve health care in rural communities across the country," said HHS Secretary Xavier Becerra. "Expanding access to substance use prevention, harm reduction, treatment, and recovery services, and improving the daily lives of mothers and children across America are priorities for the Department."
HRSA has invested nearly $384 million, including today's announcements, in community-based grants and technical assistance over the last three years through the Rural Community Opioid Response Program initiative to promote the establishment and expansion of SUD/OUD prevention, treatment, and recovery services in rural communities in 47 states and 2 territories. This includes supporting 30 existing grants focused on neonatal abstinence syndrome.
"At a time when overdose deaths are rising across America and improvements to maternal health are urgently needed, HRSA is working on multiple fronts to address the health care needs of rural Americans," said HRSA Acting Administrator Diana Espinosa. "Today's announcement furthers HRSA's commitment to improve the wellbeing of people in rural communities."
HRSA's Federal Office of Rural Health Policy is making these awards through four key programs:
The American Society of Addiction Medicine (ASAM) has announced the launch of a new, free, one-hour, online training module designed to educate medical professionals and students about prescribing buprenorphine to patients with opioid use disorder (OUD). The Buprenorphine Mini-Course: Building on Federal Prescribing Guidance module is presented by ASAM in collaboration with the American Medical Association (AMA) and Shatterproof.
Utilizing the chronic care framework of addiction treatment, the fully online module offers practical considerations for buprenorphine initiation, dosing, and ongoing patient management to prescribers seeking to initiate buprenorphine for the treatment of OUD. In addition, through interactive and application-focused learning, participants will explore the core principles of OUD treatment and the importance of language when treating patients with this chronic disease.
The brief training module is designed to expand on the Buprenorphine Quick Start Guide developed by the Substance Abuse and Mental Health Services Administration (SAMHSA). The quick start guide was released in conjunction with Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder issued by the US Department of Health and Human Services (HHS). Under the practice guidelines, which remove some of the often-cited barriers associated with the “x-waiver” to prescribe buprenorphine in-office for the treatment of OUD, eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives are exempt from federal certification requirements related to training, counseling and other ancillary services that are part of the process for obtaining a waiver to treat up to 30 patients with buprenorphine.
We encourage medical professionals and students to sign up for the module today. By taking this course, learners will help strengthen America’s medical response to OUD and increase access to life-saving medications. Plus, CME credit is available upon completion of the training module.
To sign up for the free, one-hour, online training module, please click here.
The training module will be available for free in the ASAM e-Learning Center and the AMA Ed Hub for the duration of the CME approval period (3 years). In addition, ASAM is offering its eight-hour, fully online Treatment of Opioid Use Disorder Course in the ASAM e-Learning Center for free through December 31, 2021. ASAM’s Treatment of Opioid Use Disorder Course provides eight hours of required education to qualify for a waiver to prescribe buprenorphine for OUD to more than 30 patients in an office-based setting. We encourage medical professionals and students to take advantage of these fantastic resources!
Wisconsin saw a 27.4 percent increase in drug overdose deaths last year, according to provisional federal data released this week.
There were 1,539 predicted drug overdose deaths in Wisconsin last year, compared to 1,208 the prior year, according to the Centers for Disease Control and Prevention’s National Center for Health Statistics. The total number is likely underreported due to incomplete data, per the center.
Nationally, drug overdose deaths rose over 29 percent, the largest single-year increase recorded. A total of 93,331 predicted deaths were reported in 2020, compared to 72,151 the prior year.
Overdose deaths rose in all but two states last year, with only South Dakota and New Hampshire seeing a decrease.
WMS Medigram
The Wisconsin Medical Society (Society) warned state legislators this week about a proposal that would remove two compounds from the state’s list of controlled substances that are found in leaves of the kratom tree and can have psychotropic effects. The proposal from State Assembly Representative David Murphy (R-Greenville) would also create a state regulatory system that would enable companies to sell kratom as a therapeutic product, including the ostensible ability to help people “alleviate their opioid dependency.”
Working with physician members of the Wisconsin Society of Addiction Medicine (WISAM), the Society sent a message to all 132 State Assembly Representatives and State Senators asking that they not co-author the proposal. The message from the Society included:
The proposal is spearheaded by the American Kratom Association, which has unsuccessfully lobbied the state’s Controlled Substances Board to remove the compounds from the state’s list of illegal substances. Once the proposal has circulated for legislative cosponsors, it will likely be officially introduced and assigned to a legislative committee.
Contact Society Chief Policy and Advocacy Officer Mark Grapentine, JD for more information.
Wisconsin could see more than $65 million for opioid abatement efforts through a settlement with the Sackler family and their company Purdue Pharma that’s pending approval before a bankruptcy court.
Attorney General Josh Kaul said the plan maximizes the amount Wisconsin will be able to recover. Kaul filed suit against the company two years ago.
“We’ve fought to get every dollar we can from Purdue and the Sacklers to help with the fight against the opioid epidemic,” Kaul said in a statement. “We opposed Purdue’s original bankruptcy plan, and we joined other states in negotiating for more resources to address the epidemic. Because of that multistate effort, the bankruptcy plan has improved.”
Kaul said the process has also revealed a need to reform the bankruptcy system. “It’s shameful that the Sackler family is using that process to limit their liability and that billions more can’t be recovered from them,” he added.
The state’s share of funding is around 1.8 percent of the $4.3 billion that would be paid over the next nine years. Thousands of victims would also receive compensation.
The plan permanently bans the Sacklers from the opioid business, with Purdue being sold or wound down by the end of 2024.
The Sacklers would also have to relinquish control of family foundations holding $175 million in assets to trustees of a foundation dedicated to abating the opioid crisis.
They couldn’t request or permit any new naming rights in connection with charitable or similar donations or organizations for the next nine years.
Purdue and the Sacklers would have to make public more than 30 million documents, including attorney-client privileged communications about the federal approval of painkiller OxyContin and tactics used to promote opioids.
On June 8th the Health Resources and Services Administration released the Fiscal Year 2021 Application and Program Guidance for the Substance Use Disorder Treatment and Recovery (STAR) Loan Repayment Program (LRP). The STAR-LRP will provide repayment of education loans for individuals working in a full-time substance-use disorder (SUD) treatment job that involves direct patient care at a STAR LRP-approved facility located in either a Health Professional Shortage Area (HPSA) designated for Mental Health, or a county/municipality where the average drug overdose death rate exceeds the national average.
Gov. Tony Evers on Wednesday signed into law a bill setting up a framework for distributing funds from a settlement in a lawsuit brought by Wisconsin counties and others against opioid manufacturers, distributors and retailers.
The Republican-backed bill passed the Legislature last week mostly along party-line votes. It would require the attorney general to work with counties on the settlement and splits Wisconsin’s share of settlement funds 30-70 between the state and counties that are party to the litigation.
“It will help bring much-needed funds to communities throughout Wisconsin to address the opioid pandemic,” Evers said in a statement. “These funds will be used on opioid abatement and mitigation efforts.”
Evers signed the bill over the objections of Attorney General Josh Kaul, who said the bill shouldn’t become law.
Kaul said in a statement last week that the bill would “unconstitutionally” give the Joint Finance Committee significant authority over opioid-related settlements and that the bill creates no process for legislative review of confidential materials. And he noted the bill doesn’t cap attorney's fees for opioid-related settlements.
Evers acknowledged Kaul’s concerns about the committee’s oversight.
“Despite these serious concerns, I am not willing to risk our ability to maximize the amount of settlement dollars available to Wisconsin by vetoing this bill in its entirety,” Evers said in a statement.
“I agree with the Governor that aspects of this legislation are unconstitutional,” Kaul said in a Wednesday statement. “It’s unfortunate that this new law misses the opportunity to help maximize the resources that will go toward fighting the opioid crisis in Wisconsin.”
The Wisconsin Counties Association applauded the signing.
“Without this legislation, the state and counties could have lost vital opioid abatement funds," Lance Pliml, chair of the board of the association, said in a statement. "We are grateful for Gov. Evers’ leadership in acting in the best interest of Wisconsin to get this money quickly to our local communities for mitigation and abatement efforts.
Wisconsin Society of Addiction Medicine563 Carter Court, Suite B,Kimberly, WI 54136